headquart san diego california
pure play diabet compani focus continu
reason report
price chang estim chang analysi
reiter o/v invest rate increas former
price target per share follow
compani better consensu expect
concern relat price degrad competit headwind
to-dat proven less oner expect addit despit
challeng comparison throughout expect competit
headwind fh pend launch
combin on-going market migrat pharmaci benefit
model creat potenti posit inflect prevail
favor growth rate also enhanc margin profil longer term
accordingli reiter o/v invest rate revis
month price target share
increas price increas former
price target per share recal former
per share price target assum revenu multipl
approxim versu revis price target
assum revenu multipl
increas estim increas former
billion revenu estim billion former non-gaap
earn estim per share likewis
increas former billion revenu estim
billion also increas former non-gaap earn
estim per share figur estim
tabl left
annual revenu guidanc million million
revis rang million million pre-cal
consensu million addit compani reiter
gross margin guidanc rang modestli
increas non-gaap oper margin guidanc
non-gaap ebitda margin
valuat review share current trade ev/
revenu versu compar industri peer trade like
multipl figur view rel premium
warrant base top-tier organ growth outlook within
larg modestli penetr technolog leadership
strong new product cadenc expand margin profil
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
oper highlight oper period total revenu million pre-cal consensu
million increas figur specif domest sale increas year year
million intern sale growth increas year year million dxcm quarterli gross
margin declin year year pre-cal consensu result previous mention
manufactur invest increas capac compani shift pharmaci benefit model compani
report non-gaap oper margin oper period versu oper
period net loss million per share includ million busi transit relat
cost million non-cash interest expens adjust million busi transit relat
cost million non-cash interest expens compani report non-gaap earn per share
oper period
balanc sheet review exit oper period million cash cash equival
million debt net cash posit million equival net cash per share
pipelin track conjunct earn call compani reiter previous announc event
stand serv potenti posit catalyst enhanc growth margin profil roll-out
compani new low cost transmitt associ reduct relat cog versu exist
transmitt doubl product capac commerci launch enhanc
function industry-lead offer estim late earli launch compani
much anticip next gener cgm platform
good sold
higher cog due manufactur invest shift
pbm
research develop
sell gener administr
incom prior provis incom tax
net incom continu oper
opex includ one-tim million incent charg
addit cost associ compani custom
servic organ manila
note million except per share data
compani document stephen inc estim
compani document stephen inc
dollar thousand except per share data
revenu
fiscal period
fiscal period
research develop
sell gener administr
research develop
sell gener administr
research develop
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
